This company has been acquired
Mirati Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Mirati Therapeutics has a total shareholder equity of $946.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.1B and $183.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$978.52m |
| Equity | US$946.47m |
| Total liabilities | US$183.24m |
| Total assets | US$1.13b |
Recent financial health updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Financial Position Analysis
Short Term Liabilities: MRTX's short term assets ($1.0B) exceed its short term liabilities ($137.4M).
Long Term Liabilities: MRTX's short term assets ($1.0B) exceed its long term liabilities ($45.9M).
Debt to Equity History and Analysis
Debt Level: MRTX is debt free.
Reducing Debt: MRTX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MRTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.